Published in Br J Cancer on June 14, 2004
Drug development from marine natural products. Nat Rev Drug Discov (2008) 4.08
Drug discovery from natural sources. AAPS J (2006) 2.76
Antitumour and antiangiogenic effects of Aplidin in the 5TMM syngeneic models of multiple myeloma. Br J Cancer (2008) 1.00
Antitumor peptides from marine organisms. Mar Drugs (2011) 0.99
Marine-derived angiogenesis inhibitors for cancer therapy. Mar Drugs (2013) 0.89
Phase II study of biweekly plitidepsin as second-line therapy for advanced or metastatic transitional cell carcinoma of the urothelium. Mar Drugs (2009) 0.83
CXCR4-independent rescue of the myeloproliferative defect of the Gata1low myelofibrosis mouse model by Aplidin. J Cell Physiol (2010) 0.81
Expression and correlation of CD44v6, vascular endothelial growth factor, matrix metalloproteinase-2, and matrix metalloproteinase-9 in Krukenberg tumor. World J Gastroenterol (2005) 0.80
The Chick Embryo Chorioallantoic Membrane as an In Vivo Assay to Study Antiangiogenesis. Pharmaceuticals (Basel) (2010) 0.80
Plitidepsin has a safe cardiac profile: a comprehensive analysis. Mar Drugs (2011) 0.79
Inhibition of translation by cytotrienin A--a member of the ansamycin family. RNA (2010) 0.78
Phase I study of weekly plitidepsin as 1-hour infusion combined with carboplatin in patients with advanced solid tumors or lymphomas. Invest New Drugs (2010) 0.77
The Aplidin analogs PM01215 and PM02781 inhibit angiogenesis in vitro and in vivo. BMC Cancer (2015) 0.76
CS5931, a novel polypeptide in Ciona savignyi, represses angiogenesis via inhibiting vascular endothelial growth factor (VEGF) and matrix metalloproteinases (MMPs). Mar Drugs (2014) 0.76
Plitidepsin: design, development, and potential place in therapy. Drug Des Devel Ther (2017) 0.75
Two cyclic hexapeptides from Penicillium sp. FN070315 with antiangiogenic activities. PLoS One (2017) 0.75
Angiogenesis in cancer and other diseases. Nature (2000) 28.28
Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med (1995) 26.60
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med (2002) 7.06
Clinical translation of angiogenesis inhibitors. Nat Rev Cancer (2002) 6.58
Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A (1994) 6.48
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest (2000) 5.52
Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest (2000) 3.26
The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res (1996) 2.57
Natural products in anticancer therapy. Curr Opin Pharmacol (2001) 2.45
Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol (2001) 1.84
Protein overload-induced NF-kappaB activation in proximal tubular cells requires H(2)O(2) through a PKC-dependent pathway. J Am Soc Nephrol (2002) 1.49
In vitro toxicity of ET-743 and aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors. comparison with the clinical results. Eur J Cancer (2002) 1.48
Chorioallantoic membrane capillary bed: a useful target for studying angiogenesis and anti-angiogenesis in vivo. Anat Rec (2001) 1.43
The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. Eur J Cancer (2000) 1.43
Avascular and vascular phases of tumour growth in the chick embryo. Br J Cancer (1977) 1.39
Antiproliferative effect of dehydrodidemnin B (DDB), a depsipeptide isolated from Mediterranean tunicates. Cancer Lett (1996) 1.24
Natural products as probes of cell biology: 20 years of didemnin research. Med Res Rev (2002) 1.23
GTP-dependent binding of the antiproliferative agent didemnin to elongation factor 1 alpha. J Biol Chem (1994) 1.22
New model for the study of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane: the gelatin sponge/chorioallantoic membrane assay. J Vasc Res (1998) 1.16
Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst (1995) 1.13
In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cells. Br J Cancer (1998) 1.09
Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative. Clin Cancer Res (2002) 1.09
Structure--activity relationships of the didemnins. J Med Chem (1996) 1.05
Marine organisms as a source of new anticancer agents. Lancet Oncol (2001) 1.04
Rapid and selective apoptosis in human leukemic cells induced by Aplidine through a Fas/CD95- and mitochondrial-mediated mechanism. Clin Cancer Res (2003) 0.99
Synthetic analogues of TNP-470 and ovalicin reveal a common molecular basis for inhibition of angiogenesis and immunosuppression. Bioorg Med Chem (1998) 0.99
Effect of Aplidin in acute lymphoblastic leukaemia cells. Br J Cancer (2003) 0.98
Thalidomide and immunomodulatory drugs as cancer therapy. Curr Opin Oncol (2002) 0.96
Didemnin binds to the protein palmitoyl thioesterase responsible for infantile neuronal ceroid lipofuscinosis. Proc Natl Acad Sci U S A (1996) 0.96
Effect of dehydrodidemnin B on human colon carcinoma cell lines. Anticancer Res (1997) 0.95
Cytotoxicity and neurocytotoxicity of new marine anticancer agents evaluated using in vitro assays. Cancer Chemother Pharmacol (1999) 0.94
Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine. Br J Cancer (2002) 0.91
A clinical armamentarium of marine-derived anti-cancer compounds. Anticancer Drugs (2002) 0.85
Polyamine contents of human breast cancer cells treated with the cytotoxic agents chlorpheniramine and dehydrodidemnin B. Cancer Lett (1997) 0.83
Antiangiogenic chemotherapeutic agents. Cancer Metastasis Rev (2000) 0.83
Changes in gene expression profile induced by the anticancer agent Aplidine in Molt-4 leukemic cell lines. J Biol Regul Homeost Agents (2002) 0.82
In vitro hematotoxicity of Aplidine on human bone marrow and cord blood progenitor cells. Toxicol In Vitro (2001) 0.78
Roots of clinical resistance to STI-571 cancer therapy. Science (2001) 9.78
Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor. J Cell Biol (1990) 2.69
The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res (1996) 2.57
Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice. Cancer Res (1986) 2.30
Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood (1999) 2.28
Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst (2000) 2.06
Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am J Pathol (2000) 2.05
Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer (2001) 2.02
Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol (1994) 2.01
The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. Diabet Med (2004) 1.89
Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood (1999) 1.84
Idiopathic retroperitoneal fibrosis: clinicopathologic features and differential diagnosis. Kidney Int (2007) 1.64
The combination of yondelis and cisplatin is synergistic against human tumor xenografts. Eur J Cancer (2003) 1.63
Apoptosis. Biochemical events and relevance to cancer chemotherapy. FEBS Lett (1992) 1.62
Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer. Ann Oncol (2011) 1.58
Rolling and adhesion of human tumor cells on vascular endothelium under physiological flow conditions. J Clin Invest (1993) 1.56
L-Asparagine depletion in plasma and cerebro-spinal fluid of children with acute lymphoblastic leukemia during subsequent exposures to Erwinia L-asparaginase. Ann Oncol (1996) 1.52
Metastatic behavior of tumor cells isolated from primary and metastatic human colorectal carcinomas implanted into different sites in nude mice. Cancer Res (1986) 1.47
Bone marrow angiogenesis in multiple myeloma. Leukemia (2006) 1.47
Bone mineralization and body composition in young patients with celiac disease. Am J Gastroenterol (1997) 1.46
Monitoring brevetoxins during a Gymnodinium breve red tide: comparison of sodium channel specific cytotoxicity assay and mouse bioassay for determination of neurotoxic shellfish toxins in shellfish extracts. Nat Toxins (1999) 1.46
Spectral analysis of heart rate variability in the assessment of autonomic diabetic neuropathy. J Auton Nerv Syst (1988) 1.45
Cross-calibration of eight-polar bioelectrical impedance analysis versus dual-energy X-ray absorptiometry for the assessment of total and appendicular body composition in healthy subjects aged 21-82 years. Ann Hum Biol (2003) 1.44
Pharmacokinetic interactions of paclitaxel, docetaxel and their vehicles with doxorubicin. Ann Oncol (1999) 1.42
Placenta growth factor-1 is chemotactic, mitogenic, and angiogenic. Lab Invest (1997) 1.39
Angiogenesis in rheumatoid arthritis. Histol Histopathol (2006) 1.39
Experimental nude mouse model of human colorectal cancer liver metastases. J Natl Cancer Inst (1986) 1.38
Accuracy of an eight-point tactile-electrode impedance method in the assessment of total body water. Eur J Clin Nutr (2002) 1.37
Measurement of the sequence specificity of covalent DNA modification by antineoplastic agents using Taq DNA polymerase. Nucleic Acids Res (1991) 1.34
Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer (1994) 1.34
Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc Natl Acad Sci U S A (2000) 1.34
Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer (2001) 1.31
Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. Ann Oncol (2009) 1.31
p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res (1997) 1.31
Selective DNA interaction of the novel distamycin derivative FCE 24517. Cancer Res (1991) 1.31
Metastasizing capacity of tumour cells from spontaneous metastases of transplanted murine tumours. Br J Cancer (1980) 1.29
Extensive use of peripheral angioplasty, particularly infrapopliteal, in the treatment of ischaemic diabetic foot ulcers: clinical results of a multicentric study of 221 consecutive diabetic subjects. J Intern Med (2002) 1.29
Role of aquaporin-4 water channel in the development and integrity of the blood-brain barrier. J Cell Sci (2001) 1.28
Distamycins inhibit the binding of OTF-1 and NFE-1 transfactors to their conserved DNA elements. Nucleic Acids Res (1989) 1.28
Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anti-cancer agents. Int J Cancer (1996) 1.27
In vitro and in vivo methazolastone-induced DNA damage and repair in L-1210 leukemia sensitive and resistant to chloroethylnitrosoureas. Cancer Res (1987) 1.26
Distribution of paclitaxel within the nervous system of the rat after repeated intravenous administration. Neurotoxicology (2000) 1.25
L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure. Ann Oncol (2000) 1.23
p21WAF1-derived peptides linked to an internalization peptide inhibit human cancer cell growth. Cancer Res (1997) 1.21
Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clin Cancer Res (1998) 1.21
Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogeneic bone marrow transplantation. Hum Gene Ther (1995) 1.20
An in vivo model of somatic cell gene therapy for human severe combined immunodeficiency. Science (1991) 1.19
Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma. Oncogene (2007) 1.18
Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma. Eur J Cancer (2003) 1.18
Bortezomib as an antitumor agent. Curr Pharm Biotechnol (2006) 1.17
Outbreaks of hyperkeratotic dermatitis of athymic nude mice in northern Italy. Lab Anim (1997) 1.16
Microvessel overexpression of aquaporin 1 parallels bone marrow angiogenesis in patients with active multiple myeloma. Br J Haematol (2001) 1.16
Abnormalities of peripheral blood T lymphocyte subsets in polymyalgia rheumatica. Clin Exp Rheumatol (1985) 1.15
Interleukin 1 promotes tumor cell adhesion to cultured human endothelial cells. J Clin Invest (1988) 1.14
Cell cycle-related phosphatases CDC25A and B expression correlates with survival in ovarian cancer patients. Anticancer Res (2001) 1.13
CHK1 frameshift mutations in genetically unstable colorectal and endometrial cancers. Genes Chromosomes Cancer (1999) 1.13
Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst (1995) 1.13
The heparin binding 25 kDa fragment of thrombospondin-1 promotes angiogenesis and modulates gelatinase and TIMP-2 production in endothelial cells. FASEB J (2000) 1.12
A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate. Br J Cancer (2010) 1.12
Glutathione S-transferase activity in epithelial ovarian cancer: association with response to chemotherapy and disease outcome. Ann Oncol (1997) 1.12
Tissue distribution and membrane localization of aquaporin-9 water channel: evidence for sex-linked differences in liver. J Histochem Cytochem (2001) 1.12
Inactivation of p53 in a human ovarian cancer cell line increases the sensitivity to paclitaxel by inducing G2/M arrest and apoptosis. Exp Cell Res (1998) 1.11
Differences in DNA damage produced by incorporation of 5-aza-2'-deoxycytidine or 5,6-dihydro-5-azacytidine into DNA of mammalian cells. Cancer Res (1986) 1.11
Transferrin promotes endothelial cell migration and invasion: implication in cartilage neovascularization. J Cell Biol (1997) 1.11
Introduction of wild-type p53 in a human ovarian cancer cell line not expressing endogenous p53. Nucleic Acids Res (1994) 1.10
Tubulo-interstitial lesions mediate renal damage in adriamycin glomerulopathy. Kidney Int (1986) 1.10
Matrix metalloproteinase inhibition: a review of anti-tumour activity. Ann Oncol (1995) 1.10
Accumulation of DNA strand breaks in cells exposed to methotrexate or N10-propargyl-5,8-dideazafolic acid. Cancer Res (1988) 1.10
A study of misbehavior: token reinforcement in the rat. J Exp Anal Behav (1978) 1.10
In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cells. Br J Cancer (1998) 1.09
Melanocyte tumor progression is associated with changes in angiogenesis and expression of the 67-kilodalton laminin receptor. Cancer (1993) 1.09
Sensitivity and specificity of body mass index and skinfold thicknesses in detecting excess adiposity in children aged 8-12 years. Ann Hum Biol (2003) 1.09
DNA sequence-specific adenine alkylation by the novel antitumor drug tallimustine (FCE 24517), a benzoyl nitrogen mustard derivative of distamycin. Nucleic Acids Res (1995) 1.08
Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. Eur J Cancer (2006) 1.08
Antiproliferative properties of flavone acetic acid (NSC 347512) (LM 975), a new anticancer agent. Eur J Cancer Clin Oncol (1987) 1.08
The 140-kilodalton antiangiogenic fragment of thrombospondin-1 binds to basic fibroblast growth factor. Cell Growth Differ (1997) 1.07
PARP1 is activated at telomeres upon G4 stabilization: possible target for telomere-based therapy. Oncogene (2010) 1.06
Epigenetic regulation of the ras effector/tumour suppressor RASSF2 in breast and lung cancer. Oncogene (2007) 1.06